In this Issue
Volume1, Issue 1
Glaucoma subspecialists comment on how XALATAN’s FDA approval as a first-line treatment affects clinical practice.
By ROBERT J. NOECKER, MD; PHILIP P. CHEN, MD; ROBERT D. FECHTNER, MD; AND EVE J. HIGGINBOTHAM, MD
A look at the results of a 6-month, randomized clinical trial.
By ROBERT J. NOECKER, MD
These clinical trials enable ophthalmologists to base glaucoma management more on evidence than habit.
By ROBERT D. FECHTNER, MD, AND PAUL J. LAMA, MD
Harry A. Quigley, MD, describes the insights offered by this study and the potential pitfalls involved in interpreting its results.
By GILLIAN MCDERMOTT, EDITOR-IN-CHIEF
Advice on how to maintain filtration long-term.
By MARLENE R. MOSTER, MD, AND AUGUSTO AZUARA-BLANCO, MD, PHD
Meeting the challenge of IOP control in patients for whom monotherapy has failed.
By TONY REALINI, MD
The latest on the Ex-PRESS Mini Glaucoma Shunt.